| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|:---|:---:|:---:|:---|:---|
| 28 Change in PEF (daily mean) | 1 | 92 | Mean Difference (IV, Fixed, 95% CI) | 0.30 [-9.68, 10.28] |
| 28.1 High dose oral steroid | 1 | 92 | Mean Difference (IV, Fixed, 95% CI) | 0.30 [-9.68, 10.28] |
| 29 Forced vital capacity | 7 | | WMD (Fixed, 95% CI) | 128.01 [23.79, 232.22] |
| 29.1 High dose oral steroid | 6 | | WMD (Fixed, 95% CI) | 133.15 [26.86, 239.45] |
| 29.2 Low dose oral steroid | 1 | | WMD (Fixed, 95% CI) | Not estimable |
| 30 Maximal oxygen uptake during exercise (V 02 max) | 1 | 26 | Mean Difference (IV, Fixed, 95% CI) | 0.90 [-2.15, 3.95] |
| 30.1 High dose oral steroid | 1 | 26 | Mean Difference (IV, Fixed, 95% CI) | 0.90 [-2.15, 3.95] |
| 31 Airway Hyperresponsiveness | 1 | | WMD (Fixed, 95% CI) | -0.22 [-2.26, 1.82] |
| 31.1 High dose oral steroid | 1 | | WMD (Fixed, 95% CI) | -0.22 [-2.26, 1.82] |
| 31.2 Intermediate or low dose oral steroid | 0 | | WMD (Fixed, 95% CI) | Not estimable |
| 32 Withdrawal due to exacerbations COPD | 3 | | OR (Fixed, 95% CI) | 0.44 [0.17, 1.18] |
| 32.1 High dose oral steroid | 3 | | OR (Fixed, 95% CI) | 0.44 [0.17, 1.18] |
| 33 Adverse effect: any | 3 | | OR (Fixed, 95% CI) | 7.76 [2.34, 25.70] |
| 33.1 High dose oral steroid | 3 | | OR (Fixed, 95% CI) | 7.76 [2.34, 25.70] |
| 34 Blood glucose | 1 | 42 | Mean Difference (IV, Fixed, 95% CI) | 1.72 [0.51, 2.93] |
| 34.1 High dose oral steroid | 1 | 42 | Mean Difference (IV, Fixed, 95% CI) | 1.72 [0.51, 2.93] |
| 35 Serum osteocalcin | 1 | 42 | Mean Difference (IV, Fixed, 95% CI) | -2.70 [-3.92, -1.48] |
| 35.1 High dose oral steroids | 1 | 42 | Mean Difference (IV, Fixed, 95% CI) | -2.70 [-3.92, -1.48] |

PICO 및 근거표

## Comparison 2. Oral steroid treatment >= 6 weeks

| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|:---|:---:|:---:|:---|:---|
| 1 Decrease in FEV1 (mL/year) | | | Other data | No numeric data |
| 2 Frequency of exacerbations (# exacerbations/year- median and range) | | | Other data | No numeric data |
| 3 Duration of exacerbations (# exacerbation days/year- median and range) | | | Other data | No numeric data |
| 4 # severe exacerbations COPD | 1 | | Peto Odds Ratio (Peto, Fixed, 95% CI) | Subtotals only |
| 4.1 Oral steroid (15mg +tetracycline) versus tetracycline | 1 | 55 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 1.16 [0.34, 3.99] |
| 4.2 Oral steroid (15mg + tetracycline) versus placebo | 1 | 58 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 0.33 [0.11, 0.95] |
| 5 Withdrawal due to frequent exacerbations or deterioration in lung function | 1 | | Peto Odds Ratio (Peto, Fixed, 95% CI) | Subtotals only |
| 5.1 Low dose oral steroid plus ICS versus placebo plus ICS | 1 | 40 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 8.68 [0.52, 144.35] |
| 5.2 Low dose oral steroid plus ICS versus placebo | 1 | 37 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 0.33 [0.07, 1.70] |
| 6 Overall beneficial effect of treatment | 1 | 55 | Odds Ratio (M-H, Fixed, 95% CI) | 1.06 [0.36, 3.13] |
| 6.1 Intermediate to low dose oral steroid | 1 | 55 | Odds Ratio (M-H, Fixed, 95% CI) | 1.06 [0.36, 3.13] |
| 7 Adverse effect: hypertension | 1 | | OR (Fixed, 95% CI) | 4.18 [0.57, 30.83] |
| 7.1 High dose oral steroid | 1 | | OR (Fixed, 95% CI) | 4.18 [0.57, 30.83] |
| 8 Adverse effect: glucose intolerance | 1 | | OR (Fixed, 95% CI) | 4.18 [0.57, 30.83] |
| 8.1 High dose oral steroid | 1 | | OR (Fixed, 95% CI) | 4.18 [0.57, 30.83] |
| 9 Plasma cortisol | 1 | | Mean Difference (IV, Fixed, 95% CI) | Subtotals only |
| 9.1 Low dose oral steroid plus ICS versus placebo plus ICS | 1 | 40 | Mean Difference (IV, Fixed, 95% CI) | -136.0 [-221.46, -50.54] |
| 9.2 Low dose oral steroid plus ICS versus placebo | 1 | 37 | Mean Difference (IV, Fixed, 95% CI) | -182.0 [-274.95, -89.05] |

<PAGE>127